Phase 4
Completed N=1,107
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Source: ClinicalTrials.gov NCT01248715 ↗Enrolled (actual)
1,107
Serious AEs
1.0%
Results posted
Sep 2017
Primary outcomePrimary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460
◆ Published Evidence
Established
44citations · ~6 / year
A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.
Summary
Current guidelines recommend early initiation of empiric antibiotic therapy to cover typical and atypical bacteria that may cause community-acquired pneumonia (CAP). Influenza antiviral therapy in patients with suspected or confirmed influenza. However, many clinicians do not suspect influenza among patients with CAP or other acute lower respiratory tract illness (LRTI) and often do not test for influenza. Additionally, results from currently available diagnostic tests for influenza may be delayed and several tests have low sensitivity and will give false negative results. Thus, anti-influenza treatment for patients with hospitalized influenza CAP and LRTI is frequently initiated late if at all. There is an association between delayed time to administration of empiric antibiotic therapy with increased clinical failure and mortality. As a result, empiric antibiotic therapy for patients with suspect CAP is begun within 4 - 6 hours of hospitalization. This has recently been demonstrated for delayed antiviral treatment as well. We hypothesize that, as happens with early empiric antibiotics for bacterial CAP, a standardized approach of adding early empiric anti-influenza therapy during the influenza season to hospitalized patients with suspect CAP and LRTI will improve clinical outcomes of patients with influenza associated CAP and LRTI.
To test our hypothesis we plan a prospective, randomized, multicenter clinical trial of hospitalized patients with acute LRTI, including suspect CAP, during . If early anti-influenza medications were not included on the patients admission orders, patients will be randomized to standard care, including empiric antibacterial therapy as recommended by ATS/IDSA guidelines plus standard influenza diagnostics and treatment (Standard of care) versus early initiation of empiric antiinfluenza therapy plus standard care, e.g. empiric antibacterial (oseltamivir group). The primary study outcome will be development of clinical failure and selected clinical outcomes during the 30 days after enrollment. Other clinical outcomes that will be compared between study groups include time to clinical stability, duration of hospitalization, development of cardiovascular events, re-hospitalization, short-term mortality (30 days), and long-term mortality (1 year). The secondary study outcome will be the cost-effectiveness of the intervention.
Linked Publications (3)
-
A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections.
-
Effectiveness of oseltamivir treatment on clinical failure in hospitalized patients with lower respiratory tract infection.
-
The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) |
6; 2 | .460 |
| PRIMARY Number of Participants to Transfer to ICU After 24 h |
2; 2 | .9999 |
| PRIMARY Number of Participants That Required Re-hospitalization |
5; 5 | .732 |
| PRIMARY Number of Participants That Had Short-term Mortality |
2; 1 | .9999 |
| SECONDARY Days to Reach Clinical Stability |
2; 2 | .685 |
| SECONDARY Length of Hospital Stay |
4; 4.5 | .796 |
| SECONDARY Number of Participants With Hospital Mortality. |
1; 1 | .9999 |
Eligibility Criteria
Inclusion Criteria
For oseltamivir and standard of care groups:
- 18 years of age or older
- No oseltamivir or zanamivir ordered in hospital admission orders
- Meets criteria for acute LRTI
- Signed informed consent.
Exclusion Criteria
For oseltamivir and standard of care groups:
- Oseltamivir or zanamivir ordered in hospital admission orders
- Patients hospitalized for the LRTI for more than 24 hours before enrollment into the trial.
- Patients with mental conditions who are unlikely to comply with the study protocol and who cannot give informed consent and have no guardian or proxy.
- Patients who have had severe allergic reactions such as anaphylaxis or serious skin reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, or erythema multiforme to any component of oseltamivir (TAMIFLU).
- Prisoners
Data sourced from ClinicalTrials.gov (NCT01248715) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.